These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 7403181)
21. An overview of over the counter drugs in pregnancy and lactation. Das BP; Joshi M; Pant CR Kathmandu Univ Med J (KUMJ); 2006; 4(4):545-51. PubMed ID: 18603972 [TBL] [Abstract][Full Text] [Related]
22. Prenatal cocaine exposure and child outcome: a model for the study of the infant at risk. Lester BM Isr J Psychiatry Relat Sci; 2000; 37(3):223-35. PubMed ID: 11084809 [TBL] [Abstract][Full Text] [Related]
25. Baby food as special dietary foods. Pediatrics; 1967 Nov; 40(5):922-3. PubMed ID: 6075670 [No Abstract] [Full Text] [Related]
26. Women in early phase trials: an IRB's deliberations. Anderson JR; Schonfeld TL; Kelso TK; Prentice ED IRB; 2003; 25(4):7-11. PubMed ID: 14649248 [No Abstract] [Full Text] [Related]
27. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Brinker A; Kornegay C; Nourjah P Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377 [TBL] [Abstract][Full Text] [Related]
28. Misinformation about risks of congenital anomalies. Wilson JG Prog Clin Biol Res; 1985; 163C():165-9. PubMed ID: 3991618 [No Abstract] [Full Text] [Related]
29. The pregnant dental patient. Miller MC J Calif Dent Assoc; 1995 Aug; 23(8):63-70. PubMed ID: 9052016 [TBL] [Abstract][Full Text] [Related]
30. Environmental hazards in the work setting: their effect on women of child-bearing age. Dye-White E AAOHN J; 1986 Feb; 34(2):76-8. PubMed ID: 3633193 [No Abstract] [Full Text] [Related]
31. Determination of pregnancy outcome risk rates after exposure to an intervention. Goldstein DJ; Sundell KL; DeBrota DJ; Offen WW Clin Pharmacol Ther; 2001 Jan; 69(1):7-13. PubMed ID: 11180033 [No Abstract] [Full Text] [Related]
32. Women and HIV/AIDS research: the barriers to equity. Levine C IRB; 1991; 13(1-2):18-22. PubMed ID: 11659324 [No Abstract] [Full Text] [Related]
34. Congenital anomalies secondary to maternal drug ingestion. Shane JM J Okla State Med Assoc; 1968 Nov; 61(11):529-32. PubMed ID: 5725897 [No Abstract] [Full Text] [Related]
35. CERHR conclusions would have been strengthened by a more explicit weight-of-evidence analysis. Rhomberg LR; Goodman JE Birth Defects Res B Dev Reprod Toxicol; 2008 Jun; 83(3):155-6. PubMed ID: 18570261 [No Abstract] [Full Text] [Related]
36. Monitoring and avoiding drug and chemical teratogenicity. Koren G; MacLeod SM CMAJ; 1986 Nov; 135(10):1079-81. PubMed ID: 3094926 [No Abstract] [Full Text] [Related]
37. [Migraine during pregnancy and lactation: treatment of the acute attack and non-pharmacological prophylactic strategies]. Allais G; Bosio A; Mana O; Airola G; Ciochetto D; Terzi MG; De Lorenzo C; Quirico PE; Benedetto C Minerva Med; 2003 Aug; 94(4 Suppl 1):27-38. PubMed ID: 15108609 [TBL] [Abstract][Full Text] [Related]
38. Thalidomide in America: a brush with tragedy. McFadyen RE Clio Med; 1976 Jul; 11(2):79-93. PubMed ID: 61093 [No Abstract] [Full Text] [Related]
39. Informed consent: the FDA's perspective. Bagley G Food Drug Law J; 1993; 48(2):181-6. PubMed ID: 11653141 [No Abstract] [Full Text] [Related]
40. North American antiepileptic drug pregnancy registry. Holmes LB; Wyszynski DF Epilepsia; 2004 Nov; 45(11):1465. PubMed ID: 15509251 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]